New study finds Dutch support higher drug costs, if benefits are clear
To better understand how the Dutch might prioritise cost when considering a socially acceptable price for specific medicines, researchers from Radboud University Medical Centre selected a group of 11 men and 13 women with diverse backgrounds to participate in a Citizens' Forum over two weekends.
They later ran an online survey among 884 people in the Netherlands to gather further insights and determine whether the results from the forum were broadly supported.
"The main aim of gaining insight into citizens' considerations regarding the societal acceptability of high-priced medicines was successfully achieved," lead researcher Prof. Rob Baltussen told Euractiv. Study background
The study, part of the Dutch Socially Acceptable Spending on Medicines programme (MAUG), examined medicines that are reimbursed through the Dutch basic health insurance system, which is mandatory for anyone who lives or works in the Netherlands.
Health insurers are not allowed to reimburse a medicine until the government negotiates its price with its manufacturer. These discussions take place behind closed doors.
To help the forum's participants gain more insight into the subject, an ethicist, a former senior employee of a pharmaceutical company, a senior employee of an NGO that works for fair access to medicines worldwide, and a former member of the Insured Package Advisory Committee (ACP) were enlisted to share their expertise.
"Despite the confidentiality of price negotiations, the provided information was deemed sufficient for participants to make nuanced judgements," Baltussen said.
The researchers wrote in their report that they did not select any patients to be part of the forum or questionnaire to avoid bias "because patients understandably focus primarily on their own health and access to care". Medicines offering complete recovery
The online survey used a 5-point Likert scale to measure how strongly citizens agreed with different reasons for accepting higher medicine prices.
Respondents were most supportive when a medicine offered complete recovery (4.16), enabled participation in society (3.87), or had a favourable cost-benefit ratio (3.85). Support was lowest when a medicine was significantly more expensive in the Netherlands than abroad, scoring just 1.95.
The results of the online survey largely confirmed the outcome of the Citizen Forum, that citizens are willing to accept a higher price for a medicine if it provides significant health benefits, offers fair access, and contributes to social participation. 'Reinvest 50% of profits in R&D'
Participants said the government, where necessary, should refuse to reimburse expensive medicines that are not sufficiently effective or whose prices are socially unacceptable.
They recommended that pharmaceutical manufacturers should be transparent about the price structure of medicines, set reasonable profit margins to prevent excessive prices and keep healthcare affordable.
They also said the companies should reinvest at least 50% of their profits in research and development.
The participants further recommended that citizens should understand there are limits to what the Netherlands can afford to spend on healthcare and that they should set realistic expectations.
Researchers said they expected the topic to appear regularly in the run-up to the Dutch general elections set to take place this October.
The study's results will be included in a recommendation on drug pricing to be submitted to the Health Ministry in the coming months.
"This research confirms that there is support for the difficult decisions we as a society have to make," Baltussen said. "With these insights, politicians can develop healthcare policies that are both effective and supported by society."
[Edited by Vasiliki Angouridi, Brian Maguire]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euractiv
3 days ago
- Euractiv
As the EU heats up, minds start to crack
Each month is seemingly "the hottest ever recorded", extreme weather events are frequent, and there's a general feeling that weather-as-we-know-it is no more. While this severely impacts peoples' mental health, the EU's political response is slow at best. The operators of the Brussels Mental Health emergency helpline can tell when a heatwave has arrived: 'You can feel the topic coming through when people talk to us, there's something there.' While heat is not the only reason why people call, "it's one of the reasons", an operator told Euractiv. Europe is currently the fastest-warming continent. Between 2015 and 2024, average temperatures rose by around 2.2 degrees compared to the pre-industrial era. Climate experts, too, are seeing links between heat and mental health struggles. Over the past few years, there have been repeated warnings about the strong 'negative effect' of heatwaves on mental health. Reports and studies show that heatwaves lead to a rise in hospitalisations of people with mental disorders, an increase in emergency psychiatric visits and mental health helpline calls, as well as a rise in suicide rates. In addition, people with mental health conditions are three times more likely to die during a heatwave. "People with mental and behavioural disorders – such as depression, bipolar disorder, schizophrenia or developmental disorders – are at higher risk of a deterioration in their health," WHO Programme Manager Dorota Jarosinska confirmed to Euractiv. But besides heat, climate change also brings with it a novel way to challenge mental health, namely climate anxiety: The fear linked to uncertainty about the future caused by climate change. For the first time this year, the French Agency for Ecological Transition (ADEME) measured climate anxiety – and found 10.5 million citizens affected. That's around 15% of France's population. While climate change is majorly influencing all life across the continent, those struggling with poor mental health – 84 out of 450 million EU citizens – are disproportionally affected. And those numbers don't account for climate anxiety just yet. A slow political response NGOs have demanded from politicians to do more and take psychological challenges of climate adaptation into account. "Europe needs a climate adaptation strategy that is also deeply human and social. Protecting Europeans' health is part of that, and their mental health is a vital component,' French socialist MEP Christophe Clergeau said. "It is essential to adopt a 'mental health in all policies' approach," the Brussels-based NGO Mental Health Europe completed, adding that social affairs, housing, and climate issues are often interconnected. Studies show that overcrowded housing, lack of air conditioning, as well as a lack of green spaces in combination with heatwaves increase tension and frustration, even leading to a rise in crime. Heatwaves are, in general, also correlated with an increase in aggressive behaviours and recorded domestic violence cases. However, no member of the European Parliament's housing committee was able to say whether the connection between mental health, heatwaves, and housing would be part of upcoming legislative work, when asked. On a European level, few resources are available to tackle the effects of heatwaves on mental health. The European Commission – considering mental health to be on an equal footing with physical health – is allocating €1.23 billion to mental health through around 20 initiatives, but none links mental health and climate change. In 2021, the Commission launched the European Climate and Health Observatory that – attached to the European Environment Agency – is supposed to "help the EU prepare for and adapt to the effects of climate change". But several sources have indicated to Euractiv that the Observatory's resources to work on the interlinking between climate and mental health are scarce. Action planned, rollout passive As health isn't an EU competence, the main responsibility to put measures in place lies with EU countries. But they may rely on other resources. The WHO, for example, has published its first heat guidelines in 2008. Those plans aim to strengthen preparedness, response, and risk monitoring linked to heat. Besides the recommendation to have a designated national body to coordinate the heat action plan, it includes the establishment of early warning systems, surveillance and monitoring mechanisms as well as the implementation of risk communication related to heat, and the preparation of health and social services. However, last year only 21 of the 38 European countries the WHO monitors had such a plan. In May 2026, the organisation will publish a new edition of the guidelines – which will, according to the WHO, be partly funded by the European Commission. While concrete action takes time, there seems to be a sense of awareness that current efforts need to be upped. Last October, the Hungarian EU Council Presidency and WHO/Europe organised a high-level political dialogue on the mental health impact of the triple planetary crisis – climate change, environmental pollution, and biodiversity loss. "On average, only 2% of public health expenditure is allocated to mental health... climate change will not improve any of these figures," said Alessandro Massazza, policy advisor for the NGO United for Global Health, during the event. "It will lead to an even greater burden on mental health", he concluded. (bms, vib, cs)
Euractiv
07-08-2025
- Euractiv
Robotic surgery in Poland on the rise, but access remains uneven
Poland saw a dramatic 70 per cent increase in robot-assisted surgeries in 2024, with hospitals performing around 17,100 such procedures, according to a report by the Modern Healthcare Institute. However, access varies greatly depending on the region. The report indicates that in the Mazowieckie Voivodeship, as many as 185 operations were carried out per 1,000 newly diagnosed cancer cases, whereas in the Opolskie region, only 13 were conducted. 'Regional disparities result mainly from a lack of systemic planning, financing, and a fragmented investment model,' Dr Paweł Wisz, a urologist who set a new Polish record with 491 robotic operations in six institutions, told Euractiv. 'We need a strategy: a nationwide programme of reference robotic centres, the development and funding of clinical training for teams, and reimbursement for a wider range of procedures,' he added. Dominance of urology Reports indicate that robotic surgery in Poland is largely dominated by the use of da Vinci systems, which accounted for 88 per cent of procedures in 2024, while Versius systems performed 12 per cent. Moreover, approximately 97 per cent of all robotic-assisted operations last year involved cancer treatment. Non-oncological procedures numbered around 500, primarily in cardiothoracic surgery, gynaecology, hernia repair, endometriosis, bariatric surgery, urology, and paediatrics. Of these, around 67 per cent were in urology, with prostatectomy alone making up 61 per cent of all operations. Other common urological procedures were mostly kidney cancer surgery (primarily nephron-sparing procedures) and bladder cancer (cystectomy). Of the 77 robotic surgical centres in Poland, only eight did not perform urological operations. 'Patients facing surgical treatment for prostate cancer can now choose from three methods: open surgery, laparoscopy, or robot-assisted surgery,' Dr Wisz emphasised. Regardless of the method, precision is crucial, which is essential for preserving functions such as continence and potency and, above all, for complete removal of the prostate when treating cancer. 'The use of the da Vinci robot, especially with the Collar technique, minimises the risk of leaving cancer cells behind (so-called positive margins)'. Dr Wisz notes that even when the cancer is locally advanced, research confirms better outcomes with robotic surgery. The remaining robotic procedures included colorectal cancer surgeries, which made up 13% of all operations, and gynaecological surgeries, primarily for endometrial (uterine) cancer, accounting for 12 per cent. Other procedures, making up around 5 per cent of robotic interventions in Poland, covered a range of oncological and non-oncological surgeries, including those on the pancreas, stomach, head and neck cancers, hernias, bariatric procedures, and more. Cardiac surgery accounted for about 2 per cent, with thoracic surgery comprising approximately 1 per cent of robot-assisted procedures. Equal access challenges As with any surgical procedure, one of the most crucial factors affecting not only the duration but also the success of the operation is the surgeon's experience. In Poland, over 300 doctors carry out robot-assisted surgeries. Among them, the majority, more than 200, are urologists, around 60 specialise in colorectal surgery, and about 30 focus on gynaecological procedures. In 48 hospitals that each performed at least 100 robot-assisted operations in 2024 (there were 52 such centres, though four did not provide detailed data), approximately 220 operators worked, with about 10 performing surgeries at more than one facility. The number of operators per hospital ranged from one to 12, with three hospitals having 10 or more operators. Despite growth, access to robotic surgery remains uneven. According to Dr Wisz, the technology should serve everyone, not just select regions. 'Robotic surgery has the potential to equalise opportunities rather than deepen disparities'. He believes that to genuinely increase access to robotic surgery in Poland, proven European solutions should be adopted, including the implementation of validated training systems based on measurable competencies (PBP), public, transparent medical registers that measure clinical effectiveness for patients, the use of tele-mentoring, and the creation of regional centres of competence. 'If we add to that the development of telesurgery systems allowing remote operations and training, we can level access to modern surgery across the entire country, regardless of where patients live,' he explained. Experts welcome the growing number of robotic operations across various specialities. However, Krzysztof Jakubiak, author of the report, warns that budget constraints in the National Health Fund (NFZ) may hinder this growth. Equalising funding for conventional, laparoscopic, and robotic surgeries could slow the further expansion of modern technologies in Polish hospitals. [Edited by Vasiliki Angouridi]
Euractiv
07-08-2025
- Euractiv
Sweden backs EU-wide patent reform to support drug innovation
Hoping to support pharmaceutical innovation and competitiveness, Stockholm is advocating for a Unitary Patent System. Sweden is one of eleven EU Member States pushing the Danish Presidency to finalise an EU system for enhanced patent protection for medicines. Supplementary Protection Certificates (SPCs) have been in place for several decades in the European Union. They are an intellectual property right that grants a patentholder an additional five years of patent protection, primarily for medicine patents. So far, each Member State has to implement such protection nationally, resulting in varying outcomes between countries. However, a unitary system was proposed by the EU Commission in 2023. Under this proposal, a unitary SPC would be relevant in the 18 EU states that have currently joined the so-called Unitary Patent System. 'A unitary SPC would be an important piece of the puzzle to finalise the Unitary Patent System and a reform that would boost innovation and competitiveness', Louise Petrelius, a senior advisor at the Swedish Ministry of Justice, told Euractiv. She explains that the system is expected to streamline the extension of patent protection for both medicinal and plant protection products (e.g. pesticides) in the EU by introducing a single, unified procedure across participating member states. 'This aims to simplify the current system, which requires separate applications in each country, reducing costs and administrative burden for applicants.' Longer time to market According to Petrelius, SPCs aim to compensate patent holders for the extra time it takes to bring their products to market, due to the compulsory lengthy testing and clinical trials required prior to obtaining regulatory marketing approval. The protection for patents in the EU is 20 years. An SPC could extend such a patent right for a maximum of five years. As the SPC mechanism extends the market exclusivity of a patented medicine beyond the initial patent term, it could delay the entry of generic or biosimilar competition and maintain higher prices for a longer period in the EU. According to the Swedish Intellectual Property Office (PRV), companies producing generics and biosimilars are only allowed to start manufacturing and storing a medicine during the extra five-year protection period if their products are to be exported outside the EU. Civil society organisations, as Médecins Sans Frontières (MSF), have previously called upon the EU to abolish the SPC mechanism, saying it contributes 'to high drug prices and hinders access to essential medicines by delaying the availability of generic and biosimilar alternatives'. No price analysis Johan Pontén, International Coordinator at the Swedish Dental and Pharmaceutical Benefits Agency (TLV), told Euractiv that 'TLV agrees with the Swedish government that a centralised SPC system creates more uniform and simpler management within the EU, which is positive,' adding, however: 'We have not been tasked with analysing how a changed system could affect the prices of medicines and therefore cannot comment on it'. Meanwhile, according to the Swedish Ministry of Justice, there is no ongoing discussion in the EU that links higher prices to the SPC proposal. 'Since the question of the existence of SPCs is not subject to negotiation, it is not discussed in this project. In general, my view is that Sweden is in favour of a system that promotes innovation and attractiveness on the pharmaceutical side, where intellectual property protection is an important component,' Petter Söderbäck, also a senior legal advisor at the Swedish Ministry of Justice, told Euractiv. Euractiv has requested a comment from the Danish Presidency, but has not received a response so far. [Edited by Vasiliki Angouridi]
